EORTC’s presence at EANO 2025
16 Oct 2025
EORTC will be prominently featured at the EANO 2025 conference, held in Prague from 16 to 19 October. Our team will present seven scientific abstracts, including two oral presentations and five posters, highlighting ongoing research in neuro-oncology.
In addition, EORTC projects will be featured in a joint session with the Brain Tumour Group (BTG), where six participants will present on clinical trial planning and current case studies, highlighting the collaborative efforts within EORTC to advance cancer research.
Further details can be found in the table below.
EORTC ABSTRACTS |
|
| AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE
Ogechukwu Edeh-Asogwa, Netherlands |
Friday, 17 October 10:35 - 10:45
Type: Oral session Room: Forum Hall |
| FINAL CLINICAL AND MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1P/19Q CODELETION Martin Van Den Bent, Netherlands |
Saturday, 18 October 11:25 - 11:35 Type: Oral session Room: Forum Hall |
| EANO, EORTC, EPTN and ESNR consensus-based definition for post-radiotherapy MRI abnormalities in the brain: preliminary findings from an interdisciplinary Delphi study
Maarten Lambrecht, Belgium |
Friday, 17 October 17:00 - 18:30 Type: Poster session Room: Forum Hall Foyer 3 |
| VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
Marjolein Geurts, Netherlands |
Friday, 17 October 18:00 - 19:30 Type: Poster session Room: Forum Hall Foyer 3 |
| MGMT METHYLATION DURING THE PROGRESSION OF GLIOBLASTOMA
Bo Deng, Netherlands |
Saturday, 18 October 17:00 - 18:30 Type: Poster session Room: Forum Hall Foyer 3 |
| THE USE OF EORTC QLQ-C30 SUMMARY SCORE IN CANCER CLINICAL TRIALS AND ITS PERFORMANCE AS COMPARED WITH THE GLOBAL HEALTH / QUALITY OF LIFE SCALE: A COMPARATIVE ANALYSIS OF EFFECT SIZES
Josien Scheepens, Netherlands |
Saturday, 18 October 17:00-18:30 Type: Poster session Room: Forum Hall Foyer 3 |
| ASSOCIATION BETWEEN TEMOZOLOMIDE-RELATED HEMATOLOGICAL TOXICITY AND HRQOL SCORES IN GLIOBLASTOMA: A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS
Clemens Seidel, Deutschland |
Sunday, 19 October 2025 12:00-12:45
Type: Poster session Room: Forum Hall Foyer 3 |
SESSIONS |
|
|
WHAT CAN A SUPPORTING AGENCY SUCH AS EORTC DO FOR YOU? Michael Weller, Switzerland |
JOINT SESSION Saturday, 18 October 08:00 - 08:14 South Hall 2 |
|
CLINICAL TRIAL MANAGEMENT: STEERING COMMITTEE, THE MEDICAL MONITOR AND THE DATA MONITORING COMMITTEE Patrick Roth, Switzerland |
JOINT SESSION Saturday, 18 October 08:14 - 08:28 South Hall 2 |
|
EORTC-2227 (LEGATO): LOMUSTINE WITH AND WITHOUT REIRRADIATION FOR FIRST PROGRESSION OF GLIOBLASTOMA: A RANDOMIZED PHASE III STUDY Tomas Kazda, Czech Republic |
JOINT SESSION Saturday, 18 October 08:28 - 08:36 South Hall 2 |
|
EORTC-2334 (LUMEN-1): 177LU-DOTATATE FOR RECURRENT MENINGIOMA: A RANDOMIZED PHASE II STUDY Emeline Tabouret, France |
JOINT SESSION Saturday, 18 October 08:36 - 08:44 South Hall 2 |
|
EORTC 2427 (VIGOR): VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA: A PLACEBO-CONTROLLED RANDOMIZED PHASE III STUDY Marta Padovan, Italy |
JOINT SESSION Saturday, 18 October 08:44 - 08:52 South Hall 2 |
|
EORTC-2013 (GLIO-RARE): OBSERVATIONAL STUDY FOR ASSESSING TREATMENT AND OUTCOME OF PATIENTS WITH PRIMARY BRAIN TUMOURS DIAGNOSED ACCORDING TO CIMPACT-NOW RECOMMENDATIONS AND THE 2021 WHO CLASSIFICATION Maximilian Mair, Austria |
JOINT SESSION Saturday, 18 October 08:52 - 09:00 South Hall 2 |
Related News
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
